3T Biosciences
PrivateLast Round
Series A
Aug 25, 2022
Total Funding Raised
$52M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
3T Biosciences is a biotechnology company that develops next-generation T-cell receptor (TCR)-based immunotherapies for solid tumors and immune-mediated diseases using a proprietary target discovery platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
3T Biosciences Comparables
Compare 3T Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ImmunoScape | 86% | |
| BlueSphere Bio | 84% | |
| Repertoire Immune Medicines | 84% |
3T Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 25, 2022 | ||||
| Seed | Oct 5, 2017 |
Key People
Founding team and executive leadership
3T Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Hayan Health Networks | Seed |
| Westlake Village BioPartners | Series A |
| Thiel Capital | Seed |
| Parker Institute for Cancer Immunotherapy | Seed, Series A |
| Asset Management Ventures | Seed |
| OS Fund | Seed |
| CRV | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Open roles increased to 58, 2.4x the trailing average.
- Jul 26, 2026
Monthly visitors increased 237% MoM, reaching 7.9K.
3T Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about 3T Biosciences's valuation, stock price, and market status.
Is 3T Biosciences a public or private company?
3T Biosciences is a private company.
What is the current stock price of 3T Biosciences?
3T Biosciences is a private company with no public stock price. No recent secondary market data is available.
How much is 3T Biosciences worth (valuation)?
Valuation information for 3T Biosciences is not publicly available.
Can I buy 3T Biosciences stock?
3T Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was 3T Biosciences's last funding round?
3T Biosciences's most recent funding round was Series A on August 25, 2022.
Who are the main investors in 3T Biosciences?
Key investors in 3T Biosciences include Westlake Village Biopartners.
Will 3T Biosciences IPO soon?
No public IPO plans have been announced for 3T Biosciences.
How can I track 3T Biosciences secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor 3T Biosciences's secondary market activity and sign up for updates.